Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01373424
Other study ID # IRB00046266
Secondary ID U54TR001456RDCRN
Status Completed
Phase
First received
Last updated
Start date January 2011
Est. completion date September 30, 2020

Study information

Verified date October 2020
Source Emory University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Dystonia is a disorder characterized by excessive involuntary contraction of muscles with repetitive and patterned movements. The isolated dystonias are the most common type of dystonia and include Limb dystonias (like writer's cramp), Cervical dystonia (spasmodic torticollis), Laryngeal dystonias (like spasmodic dysphonia), and Craniofacial dystonias (like blepharospasm). The purpose of this study is to create resources to help learn more about the isolated dystonias, myoclonus dystonia, and dopa-responsive dystonia and to develop and validate various dystonia rating scales.


Description:

This collaborative, international effort has one primary goal. This is to create a biospecimen repository and associated clinical database to be used as a resource for dystonia and related disease research. Across sites, the investigators hope to enroll at least 5,000 adult patients. Subjects of this study will be asked to complete a neurological exam which will be video recorded, complete some questionnaires, and donate a blood sample. A study visit will take between 45 minutes and 1 hour. All subjects will be asked to return every 1, 2, 3, or 4 years for a one hour follow-up visit. People may participate in this study without agreeing to participate in the follow-up visits.


Recruitment information / eligibility

Status Completed
Enrollment 3265
Est. completion date September 30, 2020
Est. primary completion date September 30, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with isolated dystonia or myoclonus dystonia or dopa-responsive dystonia - To be included in laryngeal dystonia group, nasolaryngoscopy (voice box exam) must have been completed to confirm diagnosis (this voice box exam is not part of the study) Exclusion Criteria: - Any evidence of a secondary cause for dystonia (other than myoclonus dystonia or dopa-responsive dystonia) - Less than 2 months since last botulinum toxin injection - Inability to provide informed consent - Significant medical or neurological conditions that preclude completing the neurological exam - Significant physical or other condition that would confound diagnosis or evaluation, other than dystonia or tremor

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Australia Westmead Hospital Westmead
Canada University of Alberta Edmonton Alberta
Canada Centre Hospitalier de l'Universite de Montreal Montreal Quebec
Canada Toronto Western Hospital Toronto Ontario
France Hopital de la Salpetriere Paris
Germany University Hospital of Schleswig-Holstein Luebeck
Italy University of Rome Rome
United Kingdom University College London Institute of Neurology London
United States University of New Mexico Albuquerque New Mexico
United States Emory University Atlanta Georgia
United States Johns Hopkins University Baltimore Maryland
United States University of Maryland Baltimore Maryland
United States National Institutes of Health Bethesda Maryland
United States University of Alabama, Birmingham Birmingham Alabama
United States Beth Israel Deaconess Medical Center Boston Massachusetts
United States Lahey Hospital and Medical Center Burlington Massachusetts
United States Rush University Chicago Illinois
United States University of Chicago Chicago Illinois
United States University of Cincinnati Cincinnati Ohio
United States University of Texas, Southwestern Dallas Texas
United States University of Colorado, Denver Denver Colorado
United States Parkinson's and Movement Disorders Center of Maryland Elkridge Maryland
United States Sanford Health - Fargo Fargo North Dakota
United States Parkinson's and Movement Disorders Institute Fountain Valley California
United States University of Florida, Gainesville Gainesville Florida
United States James Madison University Harrisonburg Virginia
United States Baylor College of Medicine Houston Texas
United States Houston Methodist Neurological Institute Houston Texas
United States University of Texas Houston Texas
United States University of Iowa Iowa City Iowa
United States Booth Gardner Parkinson's Care Center Kirkland Washington
United States University of California, San Diego La Jolla California
United States University of Tennessee Memphis Tennessee
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Mount Sinai Beth Israel New York New York
United States Mount Sinai Medical Center New York New York
United States University of Pennsylvania, Parkinson's Disease and Movement Disorders Center Philadelphia Pennsylvania
United States Virginia Commonwealth University Richmond Virginia
United States University of Rochester Rochester New York
United States Washington University in St. Louis Saint Louis Missouri
United States Mayo Clinic, Arizona Scottsdale Arizona
United States Wake Forest Winston-Salem North Carolina

Sponsors (5)

Lead Sponsor Collaborator
Emory University Allergan, Dystonia Study Group, National Institute of Neurological Disorders and Stroke (NINDS), Office of Rare Diseases (ORD)

Countries where clinical trial is conducted

United States,  Australia,  Canada,  France,  Germany,  Italy,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Observational There is no primary outcome measure as this is an observational study. 7 years
See also
  Status Clinical Trial Phase
Completed NCT01433757 - Ampicillin for DYT-1 Dystonia Motor Symptoms Phase 1
Recruiting NCT00971854 - Alteration of Deep Brain Stimulation Parameters for Dystonia N/A
Enrolling by invitation NCT00355927 - Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders. N/A
Completed NCT00169338 - Pallidal Stimulation in Patients With Post-anoxic and Idiopathic Dystonia Phase 2
Completed NCT00004421 - Deep Brain Stimulation in Treating Patients With Dystonia Phase 2/Phase 3
Terminated NCT03270189 - Effect of the Visual Information Change in Functional Dystonia N/A
Recruiting NCT02583074 - Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia N/A
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT01432899 - Studying Childhood-Onset Hemidystonia
Completed NCT04948684 - Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism
Completed NCT05106816 - The Effects of Vibrotactile Stimulation in Patients With Movement Disorders N/A
Recruiting NCT05027997 - Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Phase 2
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Active, not recruiting NCT00142259 - Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Phase 4
Recruiting NCT05663840 - Effects of Exercise on Dystonia Pathophysiology N/A
Not yet recruiting NCT06038097 - Efficacy and Safety of Radiofrequency Pallidotomy in the Management of Dystonia N/A
Recruiting NCT04286308 - Cortical-Basal Ganglia Speech Networks N/A
Active, not recruiting NCT03582891 - The Motor Network in Parkinson's Disease and Dystonia: Mechanisms of Therapy N/A
Completed NCT03318120 - Exercise Training in Dystonia N/A
Completed NCT04568681 - Deep Brain Stimulation Effects in Dystonia

External Links